Thyroid Storm-Induced Refractory Multiorgan Failure Managed by Veno-Arterial Extracorporeal Membrane Oxygenation Support: A Case-Series
American Journal of Case Reports · 2023
DOI: 10.12659/ajcr.940672 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2023. Verfasst von Mugahid Eltahir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Intensive Care Unit, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Thyroid Crisis, Extracorporeal Membrane Oxygenation. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Severe hyperthyroidism, including thyroid storm, can be precipitated by acute events, such as surgery, trauma, infection, medications, parturition, and noncompliance or stoppage of antithyroid drugs. Thyroid storm is one of the serious endocrinal emergencies that prompts early diagnosis and treatment. Early occurrence of multiorgan failure is an ominous sign that requires aggressive treatment, including the initiation of extracorporeal membrane oxygenation (ECMO) support as a bridge to stability and definitive surgical treatment. Most adverse events occur after failure of medical therapy. CASE REPORT We described 4 cases of fulminating thyroid storm that were complicated with multiple organ failure and cardiac arrest. The patients, 3 female and 1 male, were between 39 and 46 years old. All patients underwent ECMO support, with planned thyroidectomy. Three survived to discharge and 1 died after prolonged cardiac arrest and sepsis. All patients underwent peripheral, percutaneous, intensivist-led cannulation for VA-ECMO with no complications. CONCLUSIONS Early recognition of thyroid storm, identification of the cause, and proper treatment and support in the intensive care unit is essential. Patients with thyroid storm and cardiovascular collapse, who failed to improve with conventional supportive measures, had the worst prognosis, and ECMO support should be considered as a bridge until the effective therapy takes effect. Our case series showed that, in patients with life-threatening thyroid storm, VA-ECMO can be used as bridge to stabilization, definitive surgical intervention, and postoperative endocrine management. Interprofessional team management is essential, and early implantation of VA-ECMO is likely beneficial in patients with thyroid storm after failure of conventional management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Intensive Care Unit, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
- Department of Clinical Medicine, Weill Cornell Medicine, Doha, Qatar.
- Department of Endocrinology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
- Department of Surgery, Clinical Research, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
ORCID-Profile: Ayman El-Menyar, Ahmed Labib Shehatta
Zitieren
APA
Eltahir, M., Chaudhry, H., Ibrahim, E. A., Mokhtar, M., Jaouni, H., Hassan, I. F., El-Menyar, A., & Labib Shehatta, A. (2023). Thyroid Storm-Induced Refractory Multiorgan Failure Managed by Veno-Arterial Extracorporeal Membrane Oxygenation Support: A Case-Series. American Journal of Case Reports. https://doi.org/10.12659/ajcr.940672
Vancouver
Eltahir M, Chaudhry H, Ibrahim EA, Mokhtar M, Jaouni H, Hassan IF, et al. Thyroid Storm-Induced Refractory Multiorgan Failure Managed by Veno-Arterial Extracorporeal Membrane Oxygenation Support: A Case-Series. American Journal of Case Reports. 2023. doi:10.12659/ajcr.940672
BibTeX
@article{Eltahir2023,
author = {Eltahir, Mugahid and Chaudhry, Hamza and Ibrahim, Ezzeddin Abdulsalam and Mokhtar, Marwa and Jaouni, Hani and Hassan, Ibrahim Fawzy and El-Menyar, Ayman and Labib Shehatta, Ahmed},
title = {Thyroid Storm-Induced Refractory Multiorgan Failure Managed by Veno-Arterial Extracorporeal Membrane Oxygenation Support: A Case-Series},
journal = {American Journal of Case Reports},
year = {2023},
doi = {10.12659/ajcr.940672}
}
EUVIMED